Safety and Pharmacokinetics of Fluzoparib in Healthy Subjects and Those With Impaired Kidney Function

Inclusion Criteria: \- Inclusion Criteria for subjects with impaired kidney function: 1. Sign the informed consent before the trial, and fully understand the content, process, and possible adverse reactions of the trial; 2. Male or female subjects aged 18 to 70 (including 18 and 70); 3. Body mass index (BMI) ranges from 18 kg/m2 to 28 kg/m2 (including 18 and 28); 4. The glomerular filtration rate should meet the following criteria (GFR, mL/min):Subjects with mild renal impairment (CKD2): 60-89 mL/min (including 60-89);Subjects with moderate renal impairment (CKD3): 30-59 mL/min (including 30-59 ends); 5. Renal function should be stable, and the GFR results should be tested twice before administration (at least 3 days apart) within the same CKD stage. Inclusion Criteria for subjects with normal kidney function: 1. Sign the informed consent before the trial and fully understand the content, process, and possible adverse reactions of the trial; 2. Male or female subjects aged 18 to 70 (including 18 and 70); 3. Body mass index (BMI) ranges from 18 kg/m2 to 28 kg/m2 (including 18 and 28); 4. Glomerular filtration rate (GFR) ≥90 mL/min. Exclusion Criteria: \- Exclusion Criteria for subjects with impaired kidney function: 1. History of kidney transplant; 2. Need Renal dialysis during the study; 3. Urinary incontinence or anuria; 4. Clinically significant heart disease, including but not limited to: congestive heart failure, symptomatic coronary artery disease, myocardial infarction, QTcF≥470 ms (female) or QTcF≥450 ms (male) within 12 months before the start of treatment; 5. Received any investigational drug within 3 months before the study started; 6. Taking any drugs which can affect the metabolic enzyme CYP3A within 14 days before the study started; 7. Smokers and alcoholics, or those screened positive for alcohol; 8. History of drug use, or drug abuse screening positive. Exclusion Criteria for subjects with normal kidney function: 1. History of kidney transplant; 2. Clinically significant heart disease, including but not limited to: congestive heart failure, symptomatic coronary artery disease, myocardial infarction, QTcF≥470 ms (female) or QTcF≥450 ms (male) within 12 months before the start of treatment; 3. Received any investigational drug within 3 months before the study started; 4. Taking any drugs which can affect the metabolic enzyme CYP3A within 14 days before the study started; 5. Smokers and alcoholics, or those screened positive for alcohol; 6. History of drug use, or drug abuse screening positive.